Estimated GFR
The original article on estimated GFR by Lamb et al. 1 dealt with a very important and topical issue. However, we feel that the statistical and graphical methods employed signi¢cantly take from the important message of this work.
Unsurprisingly, the four creatinine data-sets had a non-Gaussian distribution, as should ideally be the case in method comparison studies. 2 For some unexplained reason, the authors then proceeded to log transform the data to produce a normal distribution. To the best of our knowledge, the only requirement before performing regression analysis is that the data exhibit a linear relationship. As a result, the regression data in Table 2 are meaningless as very few people can appreciate the signi¢cance of a slope or intercept that has been log transformed. Furthermore, the authors do not describe which version of linear regression was employed and, accordingly, we are unaware of whether the regression method used took into account any variation in the x-axis or not. When Bland and Altman described their di¡erence plot, 3 they made it clear that the data needed to exhibit a normal distribution before standard deviations (SDs) can be calculated. However, it is very clear from the second and third parts of Figure 1 that the data are not normally distributed and, accordingly, the related SD cut-o¡s in Figure 1 and the con¢-dence intervals in Table 2 are not valid. The correct di¡erence plot that should have been employed is the relative (also called percentage) di¡erence plot, as there is clearly an element of a proportional bias in the respective data.
To assess the signi¢cance of bias compared to the ID-MS method, the Wilcoxon's matched-pairs signedranks test was employed. This only compares the di¡er-ence between the medians 4 and, as a result, it is not surprising that the P-value for the bias with the Ja¡e method was not signi¢cant, as there appears to be no signi¢cant di¡erence at the median concentration. However, it is clear from Figure 1 that at low and high concentrations there is a bias of the order of 10 mmol/L. If a relative di¡erence plot and non-log-transformed Deming or Passing & Bablok were employed, we believe that the problems with the Ja¡e method may have been signi¢cant. 
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Authors' reply
We are grateful to Drs Twomey and Pledger for their close attention to, and interest in, our manuscript. 1 The creatinine data sets demonstrated a nonGaussian distribution and, as Twomey and Pledger have identi¢ed, there was a clear relationship between concentration and bias for the Roche Ja¡e and enzymatic methods. We have sympathy for the view that data become di⁄cult to appreciate following log transformation, but it is a reasonable statistical approach when undertaking linear regression analysis with non-parametric data and, indeed, the recommended approach 2 to bias plot analysis with such data. The regression analysis was a standard least-squares regression of y (Ja¡e or enzymatic creatinine assays) on x (ID-MS method), appropriate since ID-MS served as the 'gold standard' method in this study. The bias plot analysis was similarly a plot of di¡erence against ID-MS in accordance with the NCCLS EP-9A approach. All analyses were undertaken using Analyse-Itt (Analyse-it Software Ltd.,Yorkshire, UK).
The analyses described in Table 2 are therefore the bias and limits of agreement obtained following transformation and correctly describe the percentage bias. We agree that the limits of agreement and bias depicted in Figure 1 (middle and lower panels) could be considered inappropriate. However, we deliberately chose not to illustrate the log-transformed di¡erence data since, as your correspondents have pointed out, the signi¢cance of such plots are not readily appreciated.
We used the Wilcoxon's matched-pairs signed-ranks test since we believe that this is the appropriate test to use when comparing paired data-sets that are not normally distributed.We would agree that this resulted in failure to achieve a signi¢cant di¡erence for the Roche Ja¡e method versus ID-MS method comparison due to relative over-and under-recovery at low and high concentrations, respectively, as was pointed out in the text. This is well illustrated by the bias plot ( Figure 1 , lower panel) and we have quanti¢ed this effect by describing the signi¢cant relationship that existed between di¡erence (test method ID-MS) and concentration (see legend to Figure 1) .
We trust that the important message of our paper remains clear: that (standardization-related) biases in Letters Green-coloured results on guaiac-based faecal occult blood testing
The information we have available from both sides of the Atlantic strongly supports the ¢ndings reported by Gordon et al. 1 Although no formal publications exist to date, the observation of green colour on guaiac-based faecal occult blood tests (FOBT) has been reported and discussed anecdotally. The most likely origin of the colour has been considered to be the presence of bile. Since bile does not react with the guaiac, such green colours are observed to migrate away from the faecal specimen to the periphery of guaiac-impregnated paper when the developer is applied.
Our concern was that, on occasion, such green colours could mask the true presence of occult blood and could result in misinterpretation of the test result. In-house tests with blood dilutions or with spiked samples using our Hema-screen product have always displayed spreading of colour away from the area where the sample was applied, but this was never washed away entirely towards the periphery.
Based on the report of Gordon et al. 1 and the above observations, we concur with the recommendations that a test result should be considered positive if the green colour did not wash out entirely to the periphery of the guaiac paper. Conversely, if such colour does wash out, the result should be interpreted as negative.
The correct interpretation of FOBT results as described by Gordon et al. 1 could potentially result in the saving of lives, while avoiding unnecessary, uncomfortable and expensive colonoscopies for those with no blood, but bile, in their faeces.We have changed the instruction sheets of our guaiac-based FOBT products accordingly. Green-coloured results on guaiac-based faecal occult blood testing should be considered positive I read with great interest the Short Report 'Greencoloured results on guaiac-based faecal occult blood testing should be considered positive' 1 in this journal, and I wish to raise some points regarding the (pre)analytical procedure and interpretation of faecal occult blood testing (FOBT).We have been involved in FOBT for about 25 years and have used a lot of commercially available guaiac-based tests, each of which has (sometimes confusing) recommendations and instructions concerning dietary measures, analytical manipulations, and the interpretation and evaluation of results. We are now using the Hemoccult guaiac test as modi¢ed by Greegor (Beckman-Coulter Ireland Inc., Marvue, Galway, Ireland), which is also the reference test for occult blood in faeces for the German early cancer detection programme. The instructions for use are interesting because the dietary restrictions for red meat are unnecessary (but black pudding should probably be avoided). Other restrictions are as usual for FOBTs (vitamin C, etc.). Development of the slides not earlier than 48 h after the last stool sample has been applied is recommended. After applying two drops in the centre of the stool specimen area covered by guaiac paper in two rounds, the third and fourth drops may be applied if the outer ring of the moist circle has not left the area of the stool specimen. The results must be read within 60 s: the product information states that any blue on or at the edge of the specimen seen during this time period, irrespective of its intensity, indicates a positive result. No information is given for a blue-green or distinctly green colour that may be due to bile.
Our experience with the Hemoccult guaiac test is that about 30% of all positive tests develop a green colour.We use a combined approach 2 by con¢rming positive and problematic FOBT results with immoCARE-C rapid immunochromatographic assay (CARE Diagnostica, Producktions-und Vertriebgesellschaft m.b.H., Moellersdrof, Austria) for immunochemical detection of intact human haemoglobin or its early degradation products. The majority (495%) of specimens with a green colour are positive with immunochemical testing.
FOBT screening is currently the recommended screening method, with follow-up of positive tests by colonoscopy or other visualization techniques, and FOBT should therefore be accurate and sensitive enough to achieve a high analytic and diagnostic accuracy for cancers and precancerous colorectal neoplasia. In our opinion the guaiac-based tests, even socalled 'reference' or 'sensitive' tests, do not meet these requirements: they are problematic considering the preanalytical, analytical, and postanalytical points of view (especially the interpretation of spurious colour) and the high false-positive and false-negative rates. The only screening that may reach the necessary diagnostic sensitivity and speci¢city with clinically relevant positive and negative predictive values is immunochemical testing without any special dietary adjustment or specimen preparation, including delay of testing. Such screening is, in our opinion, more cost-e¡ective than guaiac testing or a combined guaiac and immunochemical approach because it cuts down on unnecessary and expensive retesting and follow-up procedures.
Milan Skitek Medical Centre Ljubljana, Clinical Institute of Clinical Chemistry and Biochemistry, Njegoševa 4, 1525 Ljubljana, Slovenia
We thank Drs Anthony and Skitek for responding to our Short Report, which recommends that green colours found with guaiac-based faecal occult blood tests (FOBT) should be reported as positive. 1 We are pleased that Immunostics Inc., the manufacturer of Hema-screen, the FOBT used in the ¢rst 2 and second colorectal cancer screening rounds in both Scotland and England, agrees with out ¢ndings. It is particularly gratifying to note that the instruction sheet for this product now includes our ¢ndings and recommendations.
Dr Skitek's data with another widely used guaiacbased FOBT support our ¢nding that green colours should be regarded as positive. Some important additional points on FOBT are also raised. We do not advocate dietary restriction for guaiac FOBT: there is a published meta-analysis which supports our view that this is unnecessary. 3 Dr Skitek states that the only possible screening approach is the use of a single immunochemical FOBT and that this is cost-e¡ective. This is opinion, however, and we refer readers to two excellent recent articles that objectively debate the advantages and disadvantages of guaiac and immunochemical FOBT and the various approaches possible for screening. 4, 5 Clearly, there is no single correct approach and the strategy adopted must be decided on a countryby-country basis, taking many factors into consideration. 4 In addition, it should be emphasized that the role of immunochemical FOBT in a population screening context has not been tested in a randomized setting. 
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Evaluation of the Elecsys NTproBNP assay
In the introduction to their paper, 1 Barnes et al. state that 'there is a need to measure BNP or NTproBNP rapidly, accurately and precisely in the laboratory', but in their conclusion the words 'rapidly' and 'accurately' are replaced by the word'easily'.What does 'easily'mean in the context of a formal method evaluation?
Firstly, a formal evaluation of an analytical method should include an assessment of trueness. The expression of N-terminal pro-B type natriuretic peptide (NTproBNP) results in method-independent SI units --ng/L --indicating that there is a primary standard containing a known mass of unambiguously de¢ned analyte to which the results of the assay system are colonoscopy or other visualization techniques, and FOBT should therefore be accurate and sensitive enough to achieve a high analytic and diagnostic accuracy for cancers and precancerous colorectal neoplasia. In our opinion the guaiac-based tests, even socalled 'reference' or 'sensitive' tests, do not meet these requirements: they are problematic considering the preanalytical, analytical, and postanalytical points of view (especially the interpretation of spurious colour) and the high false-positive and false-negative rates. The only screening that may reach the necessary diagnostic sensitivity and speci¢city with clinically relevant positive and negative predictive values is immunochemical testing without any special dietary adjustment or specimen preparation, including delay of testing. Such screening is, in our opinion, more cost-e¡ective than guaiac testing or a combined guaiac and immunochemical approach because it cuts down on unnecessary and expensive retesting and follow-up procedures.
Milan Skitek
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We thank Drs Anthony and Skitek for responding to our Short Report, which recommends that green colours found with guaiac-based faecal occult blood tests (FOBT) should be reported as positive. 1 We are pleased that Immunostics Inc., the manufacturer of Hema-screen, the FOBT used in the ¢rst 2 and second colorectal cancer screening rounds in both Scotland and England, agrees with out ¢ndings. It is particularly gratifying to note that the instruction sheet for this product now includes our ¢ndings and recommendations. Dr Skitek's data with another widely used guaiacbased FOBT support our ¢nding that green colours should be regarded as positive. Some important additional points on FOBT are also raised. We do not advocate dietary restriction for guaiac FOBT: there is a published meta-analysis which supports our view that this is unnecessary. 3 Dr Skitek states that the only possible screening approach is the use of a single immunochemical FOBT and that this is cost-e¡ective. This is opinion, however, and we refer readers to two excellent recent articles that objectively debate the advantages and disadvantages of guaiac and immunochemical FOBT and the various approaches possible for screening. 4, 5 Clearly, there is no single correct approach and the strategy adopted must be decided on a countryby-country basis, taking many factors into consideration. 4 In addition, it should be emphasized that the role of immunochemical FOBT in a population screening context has not been tested in a randomized setting. 
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Evaluation of the Elecsys NTproBNP assay
Firstly, a formal evaluation of an analytical method should include an assessment of trueness. The expression of N-terminal pro-B type natriuretic peptide (NTproBNP) results in method-independent SI units --ng/L --indicating that there is a primary standard containing a known mass of unambiguously de¢ned analyte to which the results of the assay system are Secondly, an evaluation should ideally include a split sample comparison over a range of analyte values between the ¢eld method and (1) the reference method for the analyte, to assess speci¢city and calibration; and/or (2) other ¢eld methods, to assess comparability. If there is no reference method, how can we be sure (especially in the absence of a recovery study) that the numerical results have any meaning? If there are no other ¢eld methods, then a more thorough evaluation of the only one in existence is surely essential. Some comment is required on why these elements are missing.
Thirdly, an evaluation should ideally include some recent external quality assurance (EQA) data on within-method, between-laboratory comparability, as well as data on between-method comparability (the Medicines and Healthcare products RegulatoryAgency [MHRA] 2 evaluations do this). EQA data are the only source of independent, objective assessment of ¢eld methods in regular use by clinical laboratories. Why were data from the UK NEQAS service for NTproBNP not included or commented upon?
Without these essential elements, we cannot conclude from this study whether NTproBNP is being measured with the appropriate trueness and traceability that the stated SI unitage requires.
Why is this so important? One reason is that published guidelines for this analyte with 'hard' clinical decision points, probably stated with no indication of measurement uncertainty, will be latched onto by clinicians and then ¢nd their way into national treatment protocols. If new methods are subsequently devised with improved trueness, which yield di¡erent numerical values, there will be problems of interpretation and clinical confusion.
All assays used in clinical laboratories should have optimal trueness, imprecision, reproducibility, robustness and working range, so that they possess the minimum measurement uncertainty appropriate to each clinical application. Formal evaluations of methods must adhere to protocols that are strictly enforced by editors and referees, so that they properly explore these characteristics and yield meaningful conclusions. By analogy with the STARD initiative 3 for studies of diagnostic accuracy, we should be employing universally agreed protocols for method evaluations. I do not forget, of course, that National Council for Clinical Laboratory Standards (NCCLS) 4 have a library of evaluation protocols which are widely used by the diagnostic industry and MHRA.
Jonathan Middle
UK NEQAS, PO Box 3909, Birmingham B15 3NY, UK E-mail: clinchem@ukneqas.org.uk
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Thank you for allowing us to reply to the comments raised by Dr Jonathan Middle.
The NTproBNP method used in our paper has been standardized against synthetic NTproBNP in a human serum matrix 1 and should therefore be a homogeneous molecule, quanti¢able in mass units. New methods for NTproBNP which yield di¡erent numerical values will be unlikely due to the licensing agreement for NTproBNP, so there should not be any clinical confusion over result interpretation.
There is no reference method or any other ¢eld method with which to compare the Elecsyst NTproBNP method, only in-house assays. The NTproBNP method on the E-module has since been released, but was not available at the time of this study. The method was compared with an FDA-approved method for BNP, the active hormone that is produced in an equimolar ratio with NTproBNP. The clearance of these two molecules is di¡erent and thus the two hormones circulate at di¡erent concentrations particularly in patients with heart failure. 2 We were not able to include recent EQA data on within-method, between-laboratory comparability as there is no EQA scheme for NTproBNP, although such a scheme is in development. The question then arises as to what the EQA scheme will use as source of NTproBNP and whether the samples provided will truly mimic patient samples. Unfortunately, EQA is not the 'Gold Standard'. Quis custodies ipsos custodiet?
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Department of Chemical Pathology, St George's Hospital, London E-mail: sophie.barnes@gstt.nhs.uk metrologically traceable. A recovery study, where this standard is added to a base matrix in linearly related concentrations and these samples assayed in the same run, is therefore essential.Why was this not considered worth including?
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Estimated GFR
To assess the signi¢cance of bias compared to the ID-MS method, the Wilcoxon's matched-pairs signedranks test was employed. This only compares the di¡er-ence between the medians 4 and, as a result, it is not surprising that the P-value for the bias with the Ja¡e method was not signi¢cant, as there appears to be no signi¢cant di¡erence at the median concentration. However, it is clear from Figure 1 that at low and high concentrations there is a bias of the order of 10 mmol/L. If a relative di¡erence plot and non-log-transformed Deming or Passing & Bablok were employed, we believe that the problems with the Ja¡e method may have been signi¢cant.
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